uniQure FY2025 EPS Forecast Reduced by Cantor Fitzgerald

uniQure N.V. (NASDAQ:QURE) – Research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of uniQure in a research note issued on Thursday, September 25th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of ($3.33) for the year, down from their prior forecast of ($3.31). Cantor Fitzgerald has a “Overweight” rating and a $80.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. Cantor Fitzgerald also issued estimates for uniQure’s FY2026 earnings at ($3.95) EPS.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million for the quarter, compared to analysts’ expectations of $5.00 million.

Several other brokerages have also recently issued reports on QURE. The Goldman Sachs Group raised their target price on shares of uniQure from $13.00 to $56.00 and gave the stock a “neutral” rating in a report on Thursday. Wells Fargo & Company raised their price target on shares of uniQure from $30.00 to $65.00 and gave the stock an “overweight” rating in a report on Thursday. Guggenheim upped their price objective on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Finally, UBS Group set a $95.00 price target on uniQure in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $67.17.

uniQure Price Performance

QURE opened at $54.31 on Monday. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The stock’s 50 day simple moving average is $17.44 and its 200 day simple moving average is $14.91. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -13.85 and a beta of 0.13. uniQure has a 1 year low of $4.45 and a 1 year high of $55.11.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Cubist Systematic Strategies LLC bought a new position in shares of uniQure in the 1st quarter worth about $2,562,000. OMERS ADMINISTRATION Corp purchased a new stake in uniQure in the first quarter worth about $152,000. Assenagon Asset Management S.A. increased its stake in shares of uniQure by 355.2% during the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock valued at $3,550,000 after purchasing an additional 261,323 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of uniQure during the first quarter valued at approximately $3,218,000. Finally, XTX Topco Ltd lifted its holdings in shares of uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 20,720 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Christian Klemt sold 15,000 shares of uniQure stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of the company’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares in the company, valued at approximately $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 244,316 shares of company stock valued at $10,328,181 over the last 90 days. 4.79% of the stock is currently owned by company insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.